AlphaTON Capital Corp subsidiary Cyncado Therapeutics and Australia’s Asbestos and Dust Diseases Research Institute (ADDRI) have signed a non-binding letter of intent to advance an investigator-initiated clinical trial of TT-4 in mesothelioma. The announcement was made November 12, 2025.
ADDRI will sponsor the trial in Australia. Cyncado will supply TT-4 and provide limited support under a definitive agreement to be negotiated.
The Drug: TT-4
TT-4 is Cyncado’s selective A2B adenosine receptor antagonist. Adenosine accumulates in the tumor microenvironment and suppresses immune activity through the A2B receptor. By blocking that receptor, TT-4 aims to restore immune function within the tumor.
The planned Australian trial builds on preclinical findings that Cyncado has previously shared publicly.
Filling a Gap After First-Line Therapy
The trial is designed to address the lack of a widely accepted standard of care for people with mesothelioma who have progressed after first-line treatment. Platinum-based chemotherapy combined with immunotherapy is the established first-line approach, but options narrow considerably when the disease advances.
No second-line therapy has achieved broad regulatory approval or universal guideline acceptance for mesothelioma. People who progress after first-line chemotherapy or immunotherapy face limited options outside of clinical trials.
Trial Leadership
The study will be led by Associate Professor Steven Kao, affiliated with Chris O’Brien Lifehouse and ADDRI, and Dr. Melvin Chin of Sir Charles Gairdner Hospital and the National Centre for Asbestos Related Diseases (NCARD).
Enrollment is planned for approximately 50 participants.
International Program
Cyncado describes the Australian trial as part of an international mesothelioma program running alongside planned U.S. activities. Peter Molloy, CEO of Cyncado Therapeutics, stated: “We are building an international mesothelioma program to move quickly, generate decision-quality data, and bring better options closer to patients.”
Kim Brislane, CEO of ADDRI, noted that Australia carries a significant mesothelioma burden, reflecting the country’s history of asbestos use in construction and industry.
AlphaTON Capital Corp (Nasdaq: ATON) is the parent company of Cyncado Therapeutics.
Australia’s Mesothelioma Context
Australia has one of the highest rates of mesothelioma per capita in the world, a legacy of widespread asbestos use through the 1980s. ADDRI, based in New South Wales, focuses specifically on research and support for people affected by asbestos-related diseases.
What is TT-4?▼
TT-4 is a selective A2B adenosine receptor antagonist developed by Cyncado Therapeutics. It is designed to block adenosine signaling in the tumor microenvironment, which suppresses immune activity. By blocking the A2B receptor, the drug aims to restore the ability of the immune system to attack cancer cells.
What is ADDRI?▼
ADDRI is the Asbestos and Dust Diseases Research Institute, based in Australia. It focuses on research, education, and support related to asbestos-caused diseases including mesothelioma. ADDRI will sponsor the investigator-initiated TT-4 trial in Australia.
Who will lead the Australian TT-4 trial?▼
The trial will be co-led by Associate Professor Steven Kao of Chris O’Brien Lifehouse and ADDRI, and Dr. Melvin Chin of Sir Charles Gairdner Hospital and NCARD (National Centre for Asbestos Related Diseases).
How many people will be enrolled in the trial?▼
The trial plans to enroll approximately 50 people with mesothelioma. It targets those who have already received first-line therapy, a population with limited accepted treatment options.
Is TT-4 available outside of a clinical trial?▼
No. TT-4 is an investigational drug that has not been approved by any regulatory agency. Access is through clinical trial participation only.
References
GlobeNewswire. (2025-11-12). AlphaTON Capital and Cyncado Therapeutics Announce LOI with ADDRI for TT-4 Mesothelioma Trial.
https://finance.yahoo.com/news/alphaton-cyncado-therapeutics-australia-addri-120000274.html